Blocking TIM-3 combined with PD-1 blockade overcomes the resistance to PD-1 blockade in head and neck cancer [60], and nivolumab plus ipilimumab reached enhanced anti-tumour responses in B16 melanoma, RCC, NSCLC, mesothelioma, gastro-oesophageal cancer, and hepatocellular carcinoma (HCC) [8, 61–65]. The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.